Uracil 尿嘧啶
CAS 66-22-8 MFCD00006016
信息真实价格透明
资金保障
专业采购外包团队在线服务
信息真实价格透明
资金保障
专业采购外包团队在线服务
品牌质保精细包装
现货库存
一流品牌服务
分类
- {SNA} Cell Culture, Miscellaneous Reagents and Supplements,
- {SNA} Metabolic Pathways, Metabolites and Cofactors on the Metabolic Pathways Chart, Nucleotide, Panax ginseng, Phytochemicals by Plant (Food/Spice/Herb), 代谢组学, 细胞生物学, 营养研究
- {SNA} Metabolic Pathways, Metabolites and Cofactors on the Metabolic Pathways Chart, Metabolomics, Nucleotide, Nutrition Research, Panax ginseng, Phytochemicals by Plant (Food/Spice/Herb)
- {SNA} Miscellaneous Reagents and Supplements, 细胞培养, 试剂和添加剂
- {SNA} Metabolic Pathways, Metabolites and Cofactors on the Metabolic Pathways Chart, Nucleotide, Nutrition Research, Panax ginseng,
产品应用
- 用于有机合成和生化研究,主要合成鸟苷等。
相关文献及参考
- For a review of the use of uracils as starting materials in heterocyclic synthesis, see: Adv. Het. Chem., 55, 130 (1992).
- Merck: 14,9850
- Merck: 14,9850 Beilstein:24,312
- [1]. Pałasz A, et al. In search of uracil derivatives as bioactive agents. Uracils and fused uracils: Synthesis, biological activity and applications. Eur J Med Chem. 2015 Jun 5;97:582-611.
安全信息
GHS Symbol
- S22 Do not breathe dust 不要吸入粉尘;
- S24/25 Avoid contact with skin and eyes 避免皮肤和眼睛接触;
- S26 In case of contact with eyes, rinse immediately with plenty of water and seek medical advice 眼睛接触后,立即用大量水冲洗并征求医生意见;
- S36/37/39 Wear suitable protective clothing, gloves and eye/face protection 穿戴适当的防护服、手套和眼睛/面保护;
- R36/37/38 Irritating to eyes, respiratory system and skin 对眼睛、呼吸系统和皮肤有刺激性
- P261 Avoid breathing dust/fume/gas/mist/vapours/spray. 避免吸入粉尘/烟/气体/烟雾/蒸汽/喷雾。
- P305+P351+P338
TYPE OF TEST : TD - Toxic dose (other than lowest) ROUTE OF EXPOSURE : Oral SPECIES OBSERVED : Rodent - rat DOSE/DURATION : 378 gm/kg/30W-C TOXIC EFFECTS : Tumorigenic - equivocal tumorigenic agent by RTECS criteria Kidney, Ureter, Bladder - tumors REFERENCE : CNREA8 Cancer Research. (Public Ledger Building, Suit 816, 6th & Chestnut Sts., Philadelphia, PA 19106) V.1- 1941- Volume(issue)/page/year: 46,2062,1986
TYPE OF TEST
TYPE OF TEST : TD - Toxic dose (other than lowest) ROUTE OF EXPOSURE : Oral SPECIES OBSERVED : Rodent - rat DOSE/DURATION : 235 gm/kg/20W-C TOXIC EFFECTS : Tumorigenic - equivocal tumorigenic agent by RTECS criteria Kidney, Ureter, Bladder - tumors REFERENCE : CALEDQ Cancer Letters (Shannon, Ireland). (Elsevier Scientific Pub. Ireland Ltd., POB 85, Limerick, Ireland) V.1- 1975- Volume(issue)/page/year: 34,249,1987
TYPE OF TEST : TDLo - Lowest published toxic dose ROUTE OF EXPOSURE : Oral SPECIES OBSERVED : Rodent - mouse DOSE/DURATION : 1905 gm/kg/96W-C TOXIC EFFECTS : Tumorigenic - Carcinogenic by RTECS criteria Kidney, Ureter, Bladder - tumors REFERENCE : CNREA8 Cancer Research. (Public Ledger Building, Suit 816, 6th & Chestnut Sts., Philadelphia, PA 19106) V.1- 1941- Volume(issue)/page/year: 52,1675,1992
TYPE OF TEST : TD - Toxic dose (other than lowest) ROUTE OF EXPOSURE : Oral SPECIES OBSERVED : Rodent - rat DOSE/DURATION : 454 gm/kg/36W-C TOXIC EFFECTS : Tumorigenic - equivocal tumorigenic agent by RTECS criteria Kidney, Ureter, Bladder - tumors REFERENCE : CRNGDP Carcinogenesis (London). (Oxford Univ. Press, Pinkhill House, Southfield Road, Eynsham, Oxford OX8 1JJ, UK) V.1- 1980- Volume(issue)/page/year: 12,35,1991
{hazar
TYPE OF TEST : LD50 - Lethal dose, 50 percent kill ROUTE OF EXPOSURE : Oral SPECIES OBSERVED : Rodent - rat DOSE/DURATION : >6 gm/kg TOXIC EFFECTS : Details of toxic effects not reported other than lethal dose value REFERENCE : MDACAP Medicamentos de Actualidad. (J.R. Prous, S.A., Apartado de Correos 540, 08080 Barcelona, Spain) V.1- 1965- Volume(issue)/page/year: 21,125,1985
TYPE OF TEST : LD50 - Lethal dose, 50 percent kill ROUTE OF EXPOSURE : Intraperitoneal SPECIES OBSERVED : Rodent - mouse DOSE/DURATION : 1513 mg/kg TOXIC EFFECTS : Behavioral - somnolence (general depressed activity) Behavioral - changes in motor activity (specific assay) REFERENCE : JPETAB Journal of Pharmacology and Experimental Therapeutics. (Williams & Wilkins Co., 428 E. Preston St., Baltimore, MD 21202) V.1- 1909/10- Volume(issue)/page/year: 207,504,1978
TYPE OF TEST : LD50 - Lethal dose, 50 percent kill ROUTE OF EXPOSURE : Oral SPECIES OBSERVED : Rodent - mouse DOSE/DURATION : >8 gm/kg TOXIC EFFECTS : Details of toxic effects not reported other than lethal dose value REFERENCE : OYYAA2 Oyo Yakuri. Pharmacometrics. (Oyo Yakuri Kenkyukai, CPO Box 180, Sendai 980-91, Japan) V.1- 1967- Volume(issue)/page/year: 20,1009,1980
TYPE OF TEST : LD50 - Lethal dose, 50 percent kill ROUTE OF EXPOSURE : Oral SPECIES OBSERVED : Rodent - rabbit DOSE/DURATION : >10 gm/kg TOXIC EFFECTS : Details of toxic effects not reported other than lethal dose value REFERENCE : MDACAP Medicamentos de Actualidad. (J.R. Prous, S.A., Apartado de Correos 540, 08080 Barcelona, Spain) V.1- 1965- Volume(issue)/page/year: 21,125,1985
TYPE OF TEST : LD50 - Lethal dose, 50 percent kill ROUTE OF EXPOSURE :
TYPE OF TEST : Phage inhibition capacity TEST SYSTEM : Bacteria - Escherichia coli DOSE/DURATION : 1 gm/L REFERENCE : ZAPOAK Zeitschrift fuer Allgemeine Mikrobiologie. (Akademie-Verlag GmbH, Postfach 1233, Berlin DDR-1086 Ger. Dem. Rep.) V.1- 1960- Volume(issue)/page/year: 12,583,1972
TYPE OF TEST : Cytogenetic analysis ROUTE OF EXPOSURE : Intraperitoneal TEST SYSTEM : Rodent - mouse DOSE/DURATION : 15 mg/kg REFERENCE : NULSAK Nucleus (Calcutta). (Dr. A.K. Sharma, Centre of Advanced Studies in Cell and Chromosome Research, Calcutta, 35 Baliygunge Circular Rd., Calcutta 700 019, India) V.1- 1958- Volume(issue)/page/year: 19,40,1976
TYPE OF TEST : TDLo - Lowest published toxic dose ROUTE OF EXPOSURE : Oral SPECIES OBSERVED : Rodent - rat DOSE : 15400 mg/kg SEX/DURATION : female 7-17 day(s) after conception TOXIC EFFECTS : Reproductive - Effects on Embryo or Fetus - fetotoxicity (except death, e.g., stunted fetus) Reproductive - Specific Developmental Abnormalities - musculoskeletal system REFERENCE : OYYAA2 Oyo Yakuri. Pharmacometrics. (Oyo Yakuri Kenkyukai, CPO Box 180, Sendai 980-91, Japan) V.1- 1967- Volume(issue)/page/year: 22,85,1981
TYPE OF TEST : TDLo - Lowest published toxic dose ROUTE OF EXPOSURE : Oral SPECIES OBSERVED : Rodent - rat DOSE : 616 mg/kg SEX/DURATION : female 7-17 day(s) after conception TOXIC EFFECTS : Reproductive - Effects on Newborn - sex ratio REFERENCE : OYYAA2 Oyo Yakuri. Pharmacometrics. (Oyo Yakuri Kenkyukai, CPO Box 180, Sendai 980-91, Japan) V.1- 1967- Volume(issue)/page/year: 22,85,1981
TYPE OF TEST : TDLo - Lowest published toxic dose ROUTE OF EXPOSURE : Oral SPECIES OBSERVED : Rodent - rat DOSE : 18 gm/kg SEX/DURATION : female 17-22 day(s) after conception lactating female 21 day(s) post-birth TOXIC EFFECTS : Reproductive - Specific Developmental Abnormalities - blood and lymphatic systems (including spleen and marrow) Reproductive - Specific Developmental Abnormalities - urogenital system Reproductive - Effects on Newborn - behavioral REFERENCE : OYYAA2 Oyo Yakuri. Pharmacometrics. (Oyo Yakuri Kenkyukai, CPO Box 180, Sendai 980-91, Japan) V.1- 1967- Volume(issue)/page/year: 22,109,1981
其他信息
- 图谱信息:尿嘧啶(66-22-8)质谱(MS) 尿嘧啶(66-22-8)核磁图( 1 HNMR) 尿嘧啶(66-22-8)红外图谱(IR1) 尿嘧啶(66-22-8)核磁图( 13 CNMR) 尿嘧啶(66-22-8)红外图谱(IR2)
- 下游产品:2,4-二氯嘧啶 --> 阿糖腺苷
- TCI Shanghai:尿嘧啶 Uracil,>;98.0%(LC)(T)(66-22-8)
- Sigma Aldrich:66-22-8(sigmaaldrich)
- Acros Organics:尿嘧啶 Uracil, 99+%(66-22-8)
- 有机碱:尿嘧啶是一种有机碱,是RNA中4种主要碱基之一,是核糖核酸中的一种主要嘧啶成分,也是各种尿苷酸的组成分。与核糖通过核苷键连接生成尿苷,其三磷酸化合物为尿三磷,尿三磷是核糖核酸生物合成过程中尿嘧啶的前体。尿三磷作为辅酶参与某些糖的生物合成。 尿嘧啶可阻断替加氟的降解作用,提高氟尿嘧啶的浓度,而增强抗癌作用。临床适应证与氟尿嘧啶同,主要用于消化系癌、乳腺癌及甲状腺癌等,与丝裂霉素合用于晚期胃癌疗效好。实验室通过尿素与甲酰乙酸乙酯环合而得尿嘧啶。用于医药及生化研究。 尿嘧啶存在互变异构现象: 酮式(2,4-2氧嘧啶) 烯醇式(2,4-2羟基嘧啶) 在生物细胞内主要以酮式存在。 自然界中的尿嘧啶存在于海洋生物、颗粒物和海水的溶解物中。在有机地球化学的研究中作为一种生源标示物。 嘧啶是指苯环分子的1,3位含两个氮杂原子的六元杂环化合物,与哒嗪和吡嗪互为同分异构体,由于嘧啶中存在共轭双键而具有特别的紫外光谱。嘧啶的碱性比吡啶弱,亲电取代反应也比吡啶难。但较易发生亲核取代,嘧啶衍生物广泛存在于自然界。例如维生素B1、尿嘧啶、胞嘧啶及胸腺嘧啶都含有嘧啶结构。 以上信息由Chemicalbook的晓楠编辑整理。
- 氟尿嘧啶:氟尿嘧啶简称FU,是现有最常用的抗癌药之一。白色结晶,pKa=8.1,m.p.282~283℃,微溶于水(12mg/ml25℃)和乙醇,几不溶于氯仿和醚,溶于稀酸和稀碱。在强碱中水解,在生理盐水中稳定。由于电性很强的氟原子引入,使Fu的酸性比母体尿嘧啶强30倍。Fu的注射液为以氢氧化钠调至pH9的水溶液,对光敏感,在低温或长时期室温放置析出结晶。 根据大鼠瘤组织利用嘧啶的能力比正常组织强的现象,Duschinsky和Heidelberger于1957年设计将尿嘧啶5位氢以大小相近的氟原子取代而合成Fu,作为尿嘧啶的抗代谢物以达到有选择性地抗癌作用。FU对小鼠白血病L1210、L615、腺癌755等多种动物移植性肿瘤有抑制作用。瘤细胞对它与阿糖胞苷、甲氨蝶呤、巯嘌呤、环磷酰胺和卡氮芥等常用抗癌药无交叉抗药。 FU在组织中转变为5-氟脱氧尿嘧啶核苷单磷酸酯(FDUMP)和5-氟尿嘧啶核苷三磷酸酯(FUTP)。FDUMP通过与胸腺嘧啶核苷酸合成酶(TS)和5,10-次甲基四氢叶酸成复合物而抑制TS,造成细胞内胸腺嘧啶核苷酸缺乏,抑制DNA合成,导致细胞死亡。另一方面FUTP作为RNA多聚酶的底物而掺入RNA,影响RNA的正常合成和功能。在组织培养中胸腺嘧啶核苷(TdR)能逆转FU对细胞的毒性,故多年来认为FU对DNA的影响为其抑制细胞生长的首要作用机制。但发现TdR并不能完全逆转FU的细胞毒作用,且还发现FU和TdR合并时,显著地提高FU掺入RNA而提高FU的抗癌作用。 L1210白血病细胞与6—H3—5FU培养22小时后,106Cell中有80fmol的FDUMP-TS-5,10CH2-H4叶酸的复合物,而有400fmol的FU结合至RNA中,因此强调了FU掺入RNA对其抗肿瘤作用的重要性。FU是细胞周期特异性药物,对S相作用最显著。 参考资料:中国医学百科全书编辑委员会 编;黄量 主编.中国医学百科全书。
- 100份25℃的水溶解本品0.358份。易溶于热水,微溶
- 用途一:用作医药中间体,也用于有机合成
- 尿嘧啶价格(试剂级):更新日期 产品编号 产品名称 包装 价格 2011/08/23 65012332 尿嘧啶;由雪;2,4-二羟基嘧啶;2,4-(1,3)-嘧啶二酮;2,6-二羟基1,3-二氮杂苯 5g 30.8元 2011/04/16 U0013 尿嘧啶 Uracil 25G 240元 2011/04/16 U0013 尿嘧啶 Uracil 500G 2010元